A new psychotropic phenazepam preparation

Zakusov, V. V.

doi:10.1007/bf00772264

Cited by 8 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7-bromo-5-(-2-chlorophenyl)-1,3-dihydro-1,4benzodiazepin-2-one] was developed in the Soviet Union and has been used since the 1970s as an anxiolytic, anticonvulsant and sedative-hypnotic in Russia and several Commonwealth of Independent States (1). The compound shares structural similarity with other commonly prescribed benzodiazepines, including diazepam and lorazepam (Figure 1).…”

Section: Phenazepammentioning

confidence: 99%

Reactivity of Commercial Benzodiazepine Immunoassays to Phenazepam

Kyle¹,

Brown²,

Bailey³

et al. 2012

Journal of Analytical Toxicology

View full text Add to dashboard Cite

Phenazepam is a long acting benzodiazepine that is not controlled in Canada, the United States or many European countries. The abuse of phenazepam has gained recent attention due to the number of hospitalizations and fatalities resulting from overdose. The compound is relatively potent with recommended doses of 0.5 -1.0 mg, or 1/10th the recommended dose of diazepam, and is easy to obtain locally or from international suppliers via the internet. Increased risk of phenazepam overdose is attributed to its potency and the forms in which it is supplied. Individuals without scales or balances are prone to estimate dose amounts of powder visually, which can result in significant errors. The detection of phenazepam has been described using various methods including GC, GC/MS and LC/MS, but no data regarding the sensitivity of commercially available immunoassays exist. In this study, phenazepam-spiked urine samples were analyzed using five commercial instruments and two point of care devices. The concentrations of phenazepam required for detection ranged from 140-462 ng/mL, which is comparable to those of other benzodiazepines. Laboratorians and clinicians should be confident that phenazepam will be detected via most commercial drugs of abuse screens in patients after significant ingestion.

show abstract

Section: Phenazepammentioning

confidence: 99%

Reactivity of Commercial Benzodiazepine Immunoassays to Phenazepam

Kyle¹,

Brown²,

Bailey³

et al. 2012

Journal of Analytical Toxicology

View full text Add to dashboard Cite

show abstract

“…For law enforcement purposes in traffic cases, Gjerde et al suggested legal, impairing and highly impairing limits as low as 0.0018 mg/L, 0.005 mg/L and 0.010 mg/L, respectively for phenazepam in blood [4]. The toxicity of phenazepam is lower than that of other benzodiazepines [6] and it has a long elimination halflife of 60 hours [8]. Phenazepam is metabolised by hydroxylation forming the active metabolite, 3-hydroxyphenazepam (Fig.…”

Section: Introductionmentioning

confidence: 97%

“…Phenazepam (fenazepam) [7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one] ( Fig. 1) was developed in the former USSR in the 1970s [6]. It belongs to the group of 1,4-benzodiazepines, and its structure, therapeutic dose and action mostly resemble that of lorazepam and bromazepam [7].…”

Section: Introductionmentioning

confidence: 99%